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The nonintercalative groove binding of a simplified model of olivomycin, to sequences d(CGCGCGC),, d(TATATATX, 
and d(CICICIC), is investigated. A significant preference is displayed for the minor groove of the d(CG) sequence. This 
is due predominantly to the formation of H-bonds between the hydroxyl groups on the aglycone of the drug and the 
2-amino group of the central guanine of the oligonucleotide. 
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1. INTRODUCTION 
Olivomycin, mithramycin and chromomycin As 
are antitumor glycoside antibiotics derived from 
aureolic acid which exert their action by binding to 
DNA. They possess very similar structural features 
consisting of an aglycone moiety and five attached 
hexopyranoses. The structure of one of them, 
olivomycin, is illustrated in fig. 1. Although foot- 
printing patterns obtained with the three drugs are 
not identical they do indicate a definite specificity 
of all of them for GC-rich sequences of DNA [l, 
21, a result confirmed via other physicochemical 
techniques (see e.g. [3,4]). 
Another important feature of the interaction is 
association of the specificity essentially with the 
aglycone moiety: thus, GC specificity is maintained 
upon successive limination of the sugars down to 
the derivative consisting of the aglycone and sugar 
D only [3]. However, the sugars do affect the 
strength of binding which they increase significant- 
ly, in particular by decreasing the rate of dissocia- 
tion of the DNA-drug complex [3]. 
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While there exists a general consensus on the 
above features of specificity, no understanding is 
available on the nature of the factors responsible. 
In fact, strikingly divergent opinions are held even 
as regards the fundamental characteristics of the 
interaction of these antibiotics with their nucleic 
acid receptor. Thus, while some authors [5,6] 
originally proposed an intercalative mode of 
association, they have more recently considered a 
groove binding mode [7,8], the latter being also ad- 
vocated by others [4,9,10]. In view of the data 
presented particularly in [lo] groove binding in- 
deed appears to be the most probable mode of in- 
teraction. Differences in opinion persist, however, 
among the protagonists of the groove binding 
mechanism as to whether the interaction involves 
the major [7,8] or minor [4,10] groove of DNA. 
Moreover, quite different architectures of the 
minor groove interaction were considered in the 
latter two studies, involving e.g. the interaction of 
the side-chain keto oxygen of the aglycone [4] or of 
its 011 hydroxyl [lo] with the NH2 group of 
guanine. 
Significant divergence in opinions also prevails 
as concerns the role of Mg2+ in the association. 
While it is frequently considered that the presence 
of Mg2+ constitutes an absolute requirement for 
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Fig. 1. Olivomycin. 
binding to occur [ 11,121, with, however, differing 
views on the ion’s exact role and positioning 
[3,4,10], a recent publication [13] indicates that at 
pH 4.5 binding of the drug, which is present hen in 
neutral monomeric form, does not require divalent 
cations (although the strength of binding is greatly 
enhanced in their presence). At pH > 7.0 and low 
DNA/drug ratios (< 20), metal cations are neces- 
sary, but at high DNA/drug ratios an appreciable 
proportion of the drug is bound even in the absence 
of the metal. These authors consider that the inser- 
tion of Mg’+ into the drug-DNA complex is accom- 
panied by deprotonation of the drug. Following 
[lo] the divalent cation is implied in interaction of 
the dimeric form of the drug in an anionic form 
with the DNA receptor. 
Here and as a first step towards elucidating the 
Fig.2. The reduced model of olivomycin: ASD. 
essential factors governing the groove and base se- 
quence preferences of this type of antibiotic, we 
have investigated the binding to three hepta- 
nucleotides, d(CGCGCGC)z, d(TATATAT)z and 
d(CICICIC)z, of a shortened model of olivomycin 
composed of its aglycone and its D sugar (fig.2). 
This shortened form of the natural antibiotic (sym- 
bol ASD) was considered in its neutral monomeric 
form and the interaction was investigated in the 
absence of any divalent cation. Although we are 
well aware of the fact that such a simplified model 
is far from corresponding to the usual conditions 
and mode of interaction of the natural aureolic 
acid-derived antibiotics with DNA, it seems never- 
theless plausible, on the basis of the literature re- 
viewed above, that this investigation could never- 
theless demonstrate the basic features responsible 
for the specificity of this type of drug for GC se- 
quences of DNA and yield information on their 
groove preference. 
2. METHODOLOGY 
The procedure mployed here is the Jumna method [14], used 
in similar investigations (e.g. [15,16]) described recently. The 
procedure will therefore not be repeated here. 
3. RESULTS AND DISCUSSION 
The base numbering adopted for the investigated 
double-stranded heptamers is shown in fig. 3 for 
the representative C-G sequence. The results of 
computations for the three investigated sequences 
are listed in tables 1 and 2. Table 1 reports the 
values of the ligand-oligonucleotide interaction 
energies (AEint), the conformational energy varia- 
tions of ligand (AElig), and oligonucleotide 
(AEDNA) referred to their most stable respective 
conformation energies being taken as energy zeros, 
the resulting energy balances (AE) and the dif- 
ferences (8) of energy balances with respect to the 
best value of SE being taken as energy zero. Table 
2 lists the hydrogen bond interactions that are in- 
volved in stabilization of the complexes. 
Two binding configurations were explored and 
energy-minimized for the interaction of ASD with 
the grooves of the d(CGCGCGC)z and 
d(TATATAT)z through its hydrophilic (fig.2, 
lower) or hydrophobic (fig.2, upper), side. The 
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5 volves the hydrophilic side of the chromophore 
(columns a). Structurally, this preferential 
stabilization is due essentially to hydrogen bond in- 
teractions of the hydroxyl oxygens of 011 and 012 
of the chromophore with the 2-amino group of 
guanine G4 and of the hydrogen of OH12 with 01’ 
of SS ’ . It may nevertheless be noted that the com- 
plex formed through the interaction of the hydro- 
phobic side of the drug with the same oligo- 
nucleotide (columns b) is only 1.5 kcal/mol less 
stable than the previous one. Its stabilizing interac- 
tions involve hydrogen bonds of the hydroxyl 
groups of the side chain of the aglycone with the 
amino group of G3 ’ and with 01’ of S4’ and also 
of the hydroxyl hydrogen of 021 of the chromo- 
phore with 01’ of S6’. 
5 ‘3’ 
Fig.3. Base and phosphate numbering in the heptanucleotides. 
corresponding results are presented in columns a 
and b of tables 1 and 2, respectively. 
Examination of tables 1 and 2 shows that: 
(i) The most stable association occurs in the 
minor groove of the GC oligonucleotide and in- 
(ii) The similar interactions with the minor 
groove of the AT oligonucleotide are significantly 
weaker (by 7.2 and 6.3 kcal/mol) than those cor- 
responding with the CC oligonucleotide. Although 
they also involve a series of hydrogen bonds be- 
tween the drug and the nucleic acid receptors, these 
bonds occur essentially between the proton donor 
hydroxyl groups of the aglycone side chain and dif- 
ferent acceptor oxygen atoms on the oligo- 
March 1989 
Table 1 
Values of the binding energies of ASD to d(CGCGCGC)z, d(TATATAT)z and 
d(CICICIC)2 
d(CGCGCGC)z 
(a) (b) 
d(TATATAT)z d(CICICIC)2 
(a) (b) (b) 
(1) Minor groove binding 
A&,,, -63.2 
&I -25.4 
E rep 33.5 
&sp -71.0 
A&g 3.6 
AEDNA 7.4 
6E - 52.2 
6 0.0 
(2) Major groove binding 
A&er - 52.6 
&I - 20.4 
E rep 24.6 
&sp - 56.4 
A&g 0.5 
AEDNA 8.6 
6E -43.4 
6 8.8 
- 56.9 
- 19.9 
35.5 
-72.1 
1.1 
5.0 
- 50.7 
1.5 
- 60.2 - 52.2 - 55.5 
-21.3 - 17.0 - 19.5 
31.1 25.9 31.1 
- 69.6 - 60.8 -66.8 
6.3 1.5 3.1 
8.9 4.8 6.5 
-45.1 -45.9 -45.9 
7.2 6.3 6.3 
-54.0 -43.4 
- 19.4 - 16.0 
25.6 20.7 
-59.8 -47.8 
4.4 0.0 
8.5 5.4 
-41.1 - 38.0 
11.1 14.0 
-47.8 - 52.0 
- 15.4 - 20.9 
25.3 21.7 
- 57.5 - 52.4 
1.7 4.5 
5.2 6.9 
-40.8 - 40.7 
11.4 11.6 
Energies in kcal/mol; see text for definitions 
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Table 2 
List of hydrogen-bond distances (in A) between ASD and the oligonucleotides d(CGCGCGC)a, d(TATATAT)z and d(CICICIC)z 
(a) 
d(CGCGCGC)z d(TATATAT)z d(CICICIC)z 
(b) (a) (b) (b) 
(1) Minor groove complexes 
0,2-HsN(G4)2.57 0~HzN(G3 ‘)1.95 Oi,H-02(P) 1)2.57 O,,H-O’s(P4’)2.00 Oi,H-N,(I3 ‘)2.03 
O,z-HsN(G4)2.24 O,,-Nr(G3’)2.04 OisH-02(P ’ 1)1.82 Oi,H-Os(P4’)2.58 OisH-0’ t(S4’)1.98 
HOW0’ ,(S5 ‘)2.54 O,sH-O’t(S4’)1.98 HO,a-Oz(T’4)2.00 O,sH-Oz(P4’)2.21 Oz,H-0’ ,(S6’)2.26 
Os,H-O’i(S6’)2.61 HO~O’i(S’4)2.16 02,H-O’t(S6’)2.22 
(2) Major groove complexes 
0~HaN(C3)2.15 
O,a-HaN(C2’)2.37 Oig-HzN(C3)2.06 O,,-HzN(A3’)2.46 Oi,H-O’s(P3)2.16 Oa,H-Oi(P2)1.94 
0,3-HzN(C5)2.04 HO,,-Or(P2)2.07 O,r-HzN(A4)2.23 O,,H-Ot(P3)2.57 O,,H-Oi(P4)2.54 
HOWOs(G4’)2.06 O,,H-O’s(P4)2.60 0,2-HzN(A4)2.14 O,sH-O,(P3)1.87 O,sH-Oi(P4)1.79 
HOWO,(Pl ‘)1.97 Oi,H-O,(P4)2.55 H0,2-N,(A4)2.50 Ois-HzN(A3’)2.39 022-HzN(C5)2.32 
HOWO,(P4)2.66 OisH-Ot(P4)1.78 HOid-O,(P3)1.83 
H021-O,(Pl’)2.19 
nucleotide. They are obviously unable to produce 
as strong an association as the bonds formed with 
the GC oligonucleotide by the interactions involv- 
ing the NH2 group of guanine. The interactions 
with the IC oligomer are essentially similar to those 
found with the AT oligomer. 
(iii) Energetically, the preference for the minor 
groove of GC sequences over AT sequences i  due 
essentially to the greater values of the electrostatic 
and dispersion components of the interaction 
energy and the lower DNA deformation energies in 
the former than in the latter association. 
(iv) Complexes with the major groove of the 
oligonucleotides, irrespective of the hydrophilic or 
hydrophobic side of the drug being involved, are 
in all cases significantly weaker than those formed 
in the minor groove. Binding to the AT oligo- 
nucleotide is particularly disfavored in this case. 
This decrease in affinity is due essentially to re- 
duction of the values of the electrostatic and 
dispersion components of the drug-DNA interac- 
tion energy. 
In conclusion, it seems that the ASD model of 
the aureolic acid-derived antibiotics correctly re- 
flects the major aspects of specificity in the interac- 
tion of these drugs with DNA. It confirms the 
specificity of this drug system for GC sequences, 
and moreover, supports its preference for the 
minor groove of these sequences. The major struc- 
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tural features which appear to be responsible for 
this specificity are the hydrogen bonding interac- 
tions between the hydroxyl groups 011 and 012 of 
the chromophore and the 2-amino group of 
guanine G4. 
As is well known, groove binding antibiotics 
generally show a marked specificity for the minor 
groove of AT sequences [17,181. The particular 
behavior of the aureolic acid-derived antibiotics is 
thus worth stressing. It may be observed that in the 
few cases in which binding of drugs is observed to 
the minor groove of GC sequences, they always 
seem to involve a hydrogen bonding interaction be- 
tween an oxygen atom of the drug and the 2-amino 
group of guanine on the nucleic acid receptor [19]. 
Work is being engaged presently in view of en- 
larging the model to full scale for this type of anti- 
biotic so as to determine the role in its interaction 
with DNA of the structural factors omitted here 
(e.g. the remaining sugars, Mg2+, ionization and 
possible dimerization of the drugs, etc). 
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